「网红」靶标Trop-2能成为攻克所有癌症的希望吗？

[2]. Lipinski M, Parks D R, Rouse RV, et al. Human trophoblast cell-surface antigens defined by monoclonalantibodies[J]. Proceedings of the National Academy of Sciences, 1981, 78(8):5147-5150.

[3]. McDougall A R A, Hooper S B,Zahra V A, et al. Trop2 regulates motility and lamellipodia formation incultured fetal lung fibroblasts[J]. American Journal of Physiology-LungCellular and Molecular Physiology, 2013, 305(7): L508-L521.

[4]. Tsukahara Y, Tanaka M,Miyajima A. TROP2 expressed in the trunk of the ureteric duct regulatesbranching morphogenesis during kidney development[J]. PLoS One, 2011, 6(12):e28607.

[5]. Trerotola M, Cantanelli P,Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancergrowth[J]. Oncogene, 2013, 32(2): 222-233.

[6]. Fong D, Moser P, Krammel C, etal. High expression of TROP2 correlates with poor prognosisin pancreatic cancer[J]. British journal of cancer, 2008, 99(8): 1290-1295.

[7]. Ning S, Guo S, Xie J, et al.TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma[J].Journal of Gastrointestinal Surgery, 2013, 17(2): 360-368.

[8]. Liu T, Liu Y, Bao X, et al.Overexpression of TROP2 predicts poor prognosis of patients with cervicalcancer and promotes the proliferation and invasion of cervical cancer cells byregulating ERK signaling pathway[J]. PLoS One, 2013, 8(9): e75864.

[9]. Zhao W, Zhu H, Zhang S, et al.Trop2 is overexpressed in gastric cancer and predicts poor prognosis[J].Oncotarget, 2016, 7(5): 6136.

[10]. Zeng P, Chen M B, Zhou L N, etal. Impact of TROP2 expression on prognosis in solid tumors: a systematicreview and meta-analysis[J]. Scientific reports, 2016, 6(1): 1-7.

[11]. Liao S, Wang B, Zeng R, et al.Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors[J]. Drug DevelopmentResearch, 2021, 82(8): 1096-1110.

[12]. Zaman S, Jadid H, Denson A C,et al. Targeting Trop-2 in solid tumors: future prospects[J]. OncoTargets andtherapy, 2019, 12: 1781.

[13]. Heist R S, GuarinoM J, Masters G, et al. Therapy of advanced non–small-cell lung cancer with anSN-38-anti-trop-2 drug conjugate, sacituzumab govitecan[J]. Journal of ClinicalOncology, 2017, 35(24): 2790-2797.

[14]. Gray J E, HeistR S, Starodub A N, et al. Therapy of small cell lung cancer (SCLC) with atopoisomerase-i–inhibiting antibody–drug conjugate (ADC) targeting trop-2,sacituzumab govitecan[J]. Clinical Cancer Research, 2017, 23(19): 5711-5719.

[15]. Kalinsky K,Diamond J R, Vahdat L T, et al. Sacituzumab govitecan in previously treatedhormone receptor-positive/HER2-negative metastatic breast cancer: final resultsfrom a phase I/II, single-arm, basket trial[J]. Annals of Oncology, 2020,31(12): 1709-1718.